Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elsubrutinib and upadacitinib long-term extension in systemic lupus erythematosus
2020-001690-72Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elsubrutinib and upadacitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by AbbVie Inc. Started Sep 2020; status: completed.
02
Drugs
elsubrutinibupadacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2020-001690-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001690-72.